Baseline characteristics of patients enrolled in LEMQoL, a study assessing health-related quality of life in RRMS patients treated with alemtuzumab in a real-world clinical setting

Wijmeersch B Van; F Patti; J Hobart; R Kizlaitiene; P Vanderdonckt; S Shor; AK Andreasen; BM Uitdehaag

doi:10.1111/ene.14019

Baseline characteristics of patients enrolled in LEMQoL, a study assessing health-related quality of life in RRMS patients treated with alemtuzumab in a real-world clinical setting

Wijmeersch B Van, F Patti, J Hobart, R Kizlaitiene, P Vanderdonckt, S Shor, AK Andreasen, BM Uitdehaag

Peninsula Medical School

Research output: Contribution to conference › Conference paper (not formally published) › peer-review

Original language	English
DOIs	https://doi.org/10.1111/ene.14019
Publication status	Published - Jul 2019

Access to Document

10.1111/ene.14019

Cite this

@conference{84b274392d3340bab6d1d768f7ebcd97,

title = "Baseline characteristics of patients enrolled in LEMQoL, a study assessing health-related quality of life in RRMS patients treated with alemtuzumab in a real-world clinical setting",

author = "Van, {Wijmeersch B} and F Patti and J Hobart and R Kizlaitiene and P Vanderdonckt and S Shor and AK Andreasen and BM Uitdehaag",

year = "2019",

month = jul,

doi = "10.1111/ene.14019",

language = "English",

}

TY - CONF

T1 - Baseline characteristics of patients enrolled in LEMQoL, a study assessing health-related quality of life in RRMS patients treated with alemtuzumab in a real-world clinical setting

AU - Van, Wijmeersch B

AU - Patti, F

AU - Hobart, J

AU - Kizlaitiene, R

AU - Vanderdonckt, P

AU - Shor, S

AU - Andreasen, AK

AU - Uitdehaag, BM

PY - 2019/7

Y1 - 2019/7

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000474481004025&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008

U2 - 10.1111/ene.14019

DO - 10.1111/ene.14019

M3 - Conference paper (not formally published)

ER -

Baseline characteristics of patients enrolled in LEMQoL, a study assessing health-related quality of life in RRMS patients treated with alemtuzumab in a real-world clinical setting

Access to Document

Other files and links

Cite this